HOTH Therapeutics (NASDAQ: HOTH): Developing Life-Changing Drugs for Rare Cancers and Diseases

HOTH Therapeutics was one of the sponsors for the Benzinga Biotech Small Cap Conference that took place on March 24-25, 2021. The information contained in this article in no way represents investment advice or opinion on the part of Benzinga or its writers and is intended for informational purposes only.

HOTH Therapeutics HOTH is a patient-focused clinical-stage biopharmaceutical company that specializes in the research and development of drugs that aims to rehabilitate and cure rare diseases.

mRNA Technology to Treat Cancers

Recently, HOTH announced promising news regarding two of its products. The company released a press release on April 20th detailing how its mRNA Frameshifting therapeutic significantly decreased tumor growth in mast cell tumors caused by cancer.

The science behind the mRNA is the same used in the COVID-19 vaccines that have shown great efficacy. Thus far, the quick adoption of the mRNA technology has slashed COVID spread, showed great potential for an AIDS cure, and now HOTH Therapeutics is using mRNA to treat cancer and other diseases.

Orphan Diseases

More recently, the company put out a press release on May 3rd announcing the development of HT-KIT, a drug to treat different orphan diseases. Orphan diseases are defined as rare diseases in which less than 200,000 people have them in the United States.

The HT-KIT drug works by kicking in cell signaling in a patient's body. The drug has shown promising results for the treatment of aggressive systemic mastocytosis (ASM) or mast-cell leukemia, acute myeloid leukemia (AML) and gastrointestinal stromal tumors.

There are distinct benefits that come with developing drugs for orphan diseases. The company can apply for “Orphan Drug Designation” under the Orphan Drug Act. This would allow the company to control exclusive developing and marketing rights for the drug, as well as offer a tax incentive. The tax credit would effectively cut the clinical-testing costs in half for HOTH by offering a 50% subsidy.

COVID-19

In addition to cancer and orphan disease drugs, HOTH has produced positive results from its HT-002 drug to treat COVID-19. The drug is a novel therapeutic peptide candidate that was shown to inhibit 50% of the effects of COVID-19. HOTH looks to be a promising leader in the biotechnology industry, boasting a wide array of clinical drugs that have shown promising results.

HOTH Therapeutics has a robust pipeline across several large total addressable markets (TAM) with unique, novel therapies. For more information please visit the pipeline section of the corporate website and the Investor Relations page.